Cargando…

Snus: a compelling harm reduction alternative to cigarettes

Snus is an oral smokeless tobacco product which is usually placed behind the upper lip, either in a loose form or in portioned sachets, and is primarily used in Sweden and Norway. The purpose of this review is to examine the reported effects of snus use in relation to specified health effects, namel...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Elizabeth, Thompson, Keith, Weaver, Sarah, Thompson, Joseph, O’Connell, Grant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882181/
https://www.ncbi.nlm.nih.gov/pubmed/31775744
http://dx.doi.org/10.1186/s12954-019-0335-1
_version_ 1783474099504283648
author Clarke, Elizabeth
Thompson, Keith
Weaver, Sarah
Thompson, Joseph
O’Connell, Grant
author_facet Clarke, Elizabeth
Thompson, Keith
Weaver, Sarah
Thompson, Joseph
O’Connell, Grant
author_sort Clarke, Elizabeth
collection PubMed
description Snus is an oral smokeless tobacco product which is usually placed behind the upper lip, either in a loose form or in portioned sachets, and is primarily used in Sweden and Norway. The purpose of this review is to examine the reported effects of snus use in relation to specified health effects, namely lung cancer, cardiovascular disease, pancreatic cancer, diabetes, oral cancer and non-neoplastic oral disease. The review also examines the harm reduction potential of snus as an alternative to cigarettes by comparing the prevalence of snus use and cigarette smoking, and the reported incidence of tobacco-related diseases across European Union countries. The scientific literature generally indicates that the use of snus is not a significant risk factor for developing lung cancer, cardiovascular disease, pancreatic cancer or oral cancer. Studies investigating snus use and diabetes have reported that high consumption of snus (estimated as being four or more cans per week) may be associated with a higher risk of developing diabetes or components of metabolic syndrome; however, overall results are not conclusive. Snus use is associated with the presence of non-neoplastic oral mucosal lesions which are reported to heal rapidly once use has stopped. The most recent Eurobarometer data from 2017 reported that Sweden had the lowest prevalence of daily cigarette use in the European Union at 5% whilst daily “oral tobacco” use was reported to be 20%. European data published by the World Health Organisation in 2018 indicated that Sweden had the lowest rate of tobacco-related mortality and the lowest incidence of male lung cancer. Overall, prevalence statistics and epidemiological data indicate that the use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden when compared with the rest of Europe. The available scientific data, including long-term population studies conducted by independent bodies, demonstrates that the health risks associated with snus are considerably lower than those associated with cigarette smoking.
format Online
Article
Text
id pubmed-6882181
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68821812019-12-03 Snus: a compelling harm reduction alternative to cigarettes Clarke, Elizabeth Thompson, Keith Weaver, Sarah Thompson, Joseph O’Connell, Grant Harm Reduct J Review Snus is an oral smokeless tobacco product which is usually placed behind the upper lip, either in a loose form or in portioned sachets, and is primarily used in Sweden and Norway. The purpose of this review is to examine the reported effects of snus use in relation to specified health effects, namely lung cancer, cardiovascular disease, pancreatic cancer, diabetes, oral cancer and non-neoplastic oral disease. The review also examines the harm reduction potential of snus as an alternative to cigarettes by comparing the prevalence of snus use and cigarette smoking, and the reported incidence of tobacco-related diseases across European Union countries. The scientific literature generally indicates that the use of snus is not a significant risk factor for developing lung cancer, cardiovascular disease, pancreatic cancer or oral cancer. Studies investigating snus use and diabetes have reported that high consumption of snus (estimated as being four or more cans per week) may be associated with a higher risk of developing diabetes or components of metabolic syndrome; however, overall results are not conclusive. Snus use is associated with the presence of non-neoplastic oral mucosal lesions which are reported to heal rapidly once use has stopped. The most recent Eurobarometer data from 2017 reported that Sweden had the lowest prevalence of daily cigarette use in the European Union at 5% whilst daily “oral tobacco” use was reported to be 20%. European data published by the World Health Organisation in 2018 indicated that Sweden had the lowest rate of tobacco-related mortality and the lowest incidence of male lung cancer. Overall, prevalence statistics and epidemiological data indicate that the use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden when compared with the rest of Europe. The available scientific data, including long-term population studies conducted by independent bodies, demonstrates that the health risks associated with snus are considerably lower than those associated with cigarette smoking. BioMed Central 2019-11-27 /pmc/articles/PMC6882181/ /pubmed/31775744 http://dx.doi.org/10.1186/s12954-019-0335-1 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Clarke, Elizabeth
Thompson, Keith
Weaver, Sarah
Thompson, Joseph
O’Connell, Grant
Snus: a compelling harm reduction alternative to cigarettes
title Snus: a compelling harm reduction alternative to cigarettes
title_full Snus: a compelling harm reduction alternative to cigarettes
title_fullStr Snus: a compelling harm reduction alternative to cigarettes
title_full_unstemmed Snus: a compelling harm reduction alternative to cigarettes
title_short Snus: a compelling harm reduction alternative to cigarettes
title_sort snus: a compelling harm reduction alternative to cigarettes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882181/
https://www.ncbi.nlm.nih.gov/pubmed/31775744
http://dx.doi.org/10.1186/s12954-019-0335-1
work_keys_str_mv AT clarkeelizabeth snusacompellingharmreductionalternativetocigarettes
AT thompsonkeith snusacompellingharmreductionalternativetocigarettes
AT weaversarah snusacompellingharmreductionalternativetocigarettes
AT thompsonjoseph snusacompellingharmreductionalternativetocigarettes
AT oconnellgrant snusacompellingharmreductionalternativetocigarettes